Patricia Inácio, PhD, science writer —

The International Myeloma Foundation (IMF) is one of the nonprofit organizations awarded the 2022 Amazon Web Services (AWS) IMAGINE Grant, which was established to…

The U.S. Food and Drug Administration (FDA) will review BioLineRx’s application to approve Aphexda, formerly known as motixafortide, as an add-on stem cell…

Janssen’s Tecvayli (teclistamab) has been approved for certain adults with relapsed or refractory multiple myeloma in the U.S., but access is limited due…

Note: This story was updated Sept. 26, 2022, to correct the fact that Abecma is approved for patients in Europe and Japan who have undergone…

STAR-LLD, an investigational continuous delivery of low doses of lenalidomide into the blood — being developed as a new treatment option for multiple…

Xpovio (selinexor) combined with Kyprolis (carfilzomib) and low-dose dexamethasone leads to strong and durable responses in heavily pretreated multiple myeloma patients, results…

Janssen has submitted an application to regulators in Japan seeking the approval of ciltacabtagene autoleucel, an investigational CAR T-cell therapy also known as…

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma.

The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment…